JP2017537126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537126A5 JP2017537126A5 JP2017530728A JP2017530728A JP2017537126A5 JP 2017537126 A5 JP2017537126 A5 JP 2017537126A5 JP 2017530728 A JP2017530728 A JP 2017530728A JP 2017530728 A JP2017530728 A JP 2017530728A JP 2017537126 A5 JP2017537126 A5 JP 2017537126A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- small cell
- lung cancer
- cell lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410749394.0 | 2014-12-09 | ||
| CN201410749394 | 2014-12-09 | ||
| PCT/CN2015/096777 WO2016091168A1 (zh) | 2014-12-09 | 2015-12-09 | 抗非小细胞肺癌的喹啉衍生物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537126A JP2017537126A (ja) | 2017-12-14 |
| JP2017537126A5 true JP2017537126A5 (enExample) | 2020-03-05 |
| JP6865684B2 JP6865684B2 (ja) | 2021-04-28 |
Family
ID=56106719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530728A Active JP6865684B2 (ja) | 2014-12-09 | 2015-12-09 | 非小細胞肺癌に対するキノリン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10307412B2 (enExample) |
| EP (1) | EP3231797B1 (enExample) |
| JP (1) | JP6865684B2 (enExample) |
| CN (1) | CN107001326B (enExample) |
| AU (1) | AU2015360095B2 (enExample) |
| ES (1) | ES2793286T3 (enExample) |
| WO (1) | WO2016091168A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| AU2015360095B2 (en) | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| EP3319602B1 (en) | 2015-07-11 | 2020-02-05 | Advenchen Pharmaceuticals LLC | Fused quinoline compounds as pi3k/mtor inhibitors |
| CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
| CN111936467B (zh) | 2018-03-02 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途 |
| CN116440134A (zh) * | 2018-05-22 | 2023-07-18 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
| CN116077647B (zh) * | 2018-07-18 | 2025-06-27 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| SG11202102682SA (en) * | 2018-09-18 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Quinoline derivative used for treating small cell lung cancer |
| CN112638385B (zh) * | 2018-09-18 | 2023-03-31 | 正大天晴药业集团股份有限公司 | 用于治疗脑肿瘤的喹啉衍生物 |
| BR112021017678A2 (pt) * | 2019-03-07 | 2021-11-16 | Advenchen Pharmaceuticals Llc | Uso de catequentinibe (anlotinibe) combinando com quimioterapia padrão ou imunoterapia em ordem sequencial para o tratamento de câncer |
| CN113613674B (zh) * | 2019-03-15 | 2024-11-05 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
| CN112274511B (zh) * | 2019-07-22 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 用于治疗移植物抗宿主病的喹啉衍生物 |
| AU2020356356A1 (en) * | 2019-09-25 | 2022-05-12 | Debiopharm International S.A. | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| WO2021104319A1 (zh) * | 2019-11-25 | 2021-06-03 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物或其盐的联用药物组合物及其用途 |
| CN114929225B (zh) * | 2020-01-19 | 2024-06-28 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
| CN120154618B (zh) * | 2025-05-15 | 2025-11-18 | 正大天晴药业集团股份有限公司 | 格索雷塞用于治疗肺癌的用途或其药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| RU2478387C2 (ru) | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| IT1393351B1 (it) | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
| CN103664892B (zh) | 2010-08-01 | 2015-09-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| EP2780341B1 (en) * | 2011-11-14 | 2019-02-13 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | Kinase modulating compounds, compositions containing the same and use thereof |
| EP2945931A4 (en) | 2013-01-18 | 2016-10-12 | Advenchen Pharmaceuticals Llc | PROCESS FOR THE PREPARATION OF ANTITUMOR AGENT, 6- (7 - ((1-AMINO-CYCLO-PROPYL) -METHOXY) -6-METHOXYQUINOLIN-4-YLOXY) -N-METHYL-1-NAPHTHAMIDE, AND His crystalline form |
| CN104513229A (zh) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| CN105311030B (zh) * | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| EP3169687B1 (en) | 2014-07-14 | 2019-01-02 | Advenchen Pharmaceuticals, Nanjing Ltd. | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |
| AU2015360095B2 (en) | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| EP3319602B1 (en) | 2015-07-11 | 2020-02-05 | Advenchen Pharmaceuticals LLC | Fused quinoline compounds as pi3k/mtor inhibitors |
| CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
-
2015
- 2015-12-09 AU AU2015360095A patent/AU2015360095B2/en not_active Ceased
- 2015-12-09 CN CN201580066275.8A patent/CN107001326B/zh active Active
- 2015-12-09 WO PCT/CN2015/096777 patent/WO2016091168A1/zh not_active Ceased
- 2015-12-09 JP JP2017530728A patent/JP6865684B2/ja active Active
- 2015-12-09 ES ES15867543T patent/ES2793286T3/es active Active
- 2015-12-09 EP EP15867543.9A patent/EP3231797B1/en active Active
- 2015-12-09 US US15/533,873 patent/US10307412B2/en active Active
-
2019
- 2019-04-12 US US16/383,288 patent/US10888559B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009090A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| CN107296811B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2016534063A5 (enExample) | ||
| JP2013522212A5 (enExample) | ||
| RU2734260C2 (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| JP2015511638A5 (enExample) | ||
| JP2015038149A5 (enExample) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2013519632A5 (enExample) | ||
| JP2005526741A5 (enExample) | ||
| JP2010521417A5 (enExample) | ||
| JP2014524469A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2016529285A5 (enExample) | ||
| JP2020500868A5 (enExample) | ||
| JP2024531188A5 (enExample) | ||
| JP2012502103A5 (enExample) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JP2023011549A5 (enExample) | ||
| PH12022550917A1 (en) | Use of phenylquinolinones and flavonoid derivatives for treating neuropathic pain | |
| JP2015221806A5 (enExample) | ||
| JP2021091608A5 (enExample) | ||
| CN112105361A (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 |